Compare Boston Scientific Corporation (BSX) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs GE Vernova Inc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while GE Vernova Inc trades at $1,077 (market cap $286.46B). The key difference: GE Vernova Inc is far larger — about 4.3× Boston Scientific Corporation's market cap, and GE Vernova Inc pays a 0.19% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | GEV | |
|---|---|---|
Market Cap | $66.37B | $286.46B |
Sector | Health | Technology |
52-Week High | $108.14 | $1.17K |
52-Week Low | $42.63 | $547.96 |
Enterprise Value | $75.94B | $279.09B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
GE Vernova (GEV) trades at $1,042.60, down 4.49% today, amid mixed technical signals but strong fundamental momentum. The stock shows bullish moving averages and oversold RSI conditions, while recent earnings beats and a 23.81% net income margin highlight robust profitability. Analyst consensus remains strongly bullish with a $1,240 price target, supported by the company's $11 billion investment in grid reliability and nuclear energy expansion.
Outlook: GEV's leadership in AI power infrastructure and nuclear technology positions it for long-term growth, though high valuation multiples (P/E 31.15) and execution risks on capital investments warrant caution. Near-term catalysts include Q2 2026 earnings on July 22, 2026, and dividend payments in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
